This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Reasons Why Bruker (BRKR) Is a Great Growth Stock
by Zacks Equity Research
Bruker (BRKR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Bruker (BRKR) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Bruker (BRKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.
Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.
Why Is Bruker (BRKR) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
Here's Why Momentum Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Bruker Corporation (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
3 Reasons Growth Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Transcat, Inc. (TRNS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Transcat, Inc. (TRNS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Emcore (EMKR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Emcore (EMKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
The Zacks Analyst Blog Highlights: Continental Resources, United Parcel Service, Bruker Corp, Molina Healthcare and CDW Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Continental Resources, United Parcel Service, Bruker Corp, Molina Healthcare and CDW Corp
Top 5 Growth Picks Amid Disappointing April Jobs Data
by Nalak Das
We have narrowed down our search to five growth stocks that have popped more than 25 % year to date and still have upside left for 2021. These are: UPS, CLR, MOH, CDW, and BRKR
Large-Cap Stocks Bring Stability to Your Portfolio
by Sejuti Banerjea
Large-caps bring stability to your portfolio because they don't react as aggressively to news and other events.
All You Need to Know About Bruker (BRKR) Rating Upgrade to Buy
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Bruker (BRKR) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Bruker Corp (BRKR) Stock Might be a Great Pick
by Zacks Equity Research
Bruker Corp (BRKR) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Bruker (BRKR) Rides on Product Launches Amid COVID-19 Woes
by Zacks Equity Research
Within Bruker's (BRKR) Nano Group Semiconductor metrology revenues have been steady with order rates improving as semi metrology equipment markets are witnessing a rebound.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.